Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months

Sana Biotechnology, Inc.

Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.
Expects $40-45M non-cash impairment on Bothell/Seattle facilities due to sublease plans and manufacturing shift.
Raised $29.1M net proceeds via ATM sale of 7.44M shares between April 1 and August 6, 2025.
UP421 trial meets all endpoints: transplanted beta cells survive, produce insulin, evade immune detection at 6 months.
Sonja Schrepfer, SVP and Head of Hypoimmune Platform, resigned to pursue other opportunities.

item 2.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.